Exchanges: NASDAQ | NYSE | XLON | AMS | ADS | TSE | BRU

Company Profile

Previous Hold Today AKTX ranks #2321 as HOLD CANDIDATE #2321 Next Hold

Akari Therapeutics Plc stock forecast

AKTX stock forecast

Akari Therapeutics Plc

24 West 40th Street

New York, NY 10018


Industry: Drugs - Generic

Sector: Healthcare


Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation C5 complement inhibitor that is in Phase Ib clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. The company is based in New York, New York. Akari Therapeutics, Plc is a subsidiary of RPC Pharma Limited.

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank